OncoQuest, Tesaro Team Up to Test Oregovomab-Zejula Combo

OncoQuest, Tesaro Team Up to Test Oregovomab-Zejula Combo
OncoQuest has entered into a collaborative agreement with Tesaro to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab (MAb B43.13) with Zejula (niraparib) in recurrent ovarian cancer. Oregovomab is a high-affinity monoclonal antibody designed to bind to the tumor-associated antigen CA125 and initiate a cascade of immune responses against this protein. CA125 is expressed at the surface of epithelial ovarian cancer cells, but it is also shed into circulation. OncoQuest is studying if combining standard of care chemotherapy — Paraplatin (carboplatin) plus Taxol (paclitaxel) — with oregovomab can improve outcomes when compared to chemotherapy alone. "We are excited to work with TESARO, an oncology-focused biopharmaceutical company, to evaluate the possible synergistic effects of combining Zejula with oregovomab in this important clinical setting," Madi Madiyalakan, chief executive officer of OncoQuest, said in a press release. The company had already shown that the combination delayed disease progression when given to advanced ovarian cancer patients following surgery. The findings, presented at the American Society of Clinical Oncology meeting in June 2017, were included in a poster titled, “
Subscribe or to access all post and page content.